PTGS2 and colorectal carcinoma: The anti-neoplastic properties of these agents result from the inhibition of prostaglandin generation, particularly that of prostaglandin E2 (PGE2), the most abundant in vivo product of COX-2 activity in CRC cells (Pugh and Thomas, 1994; Rigas et al, 1993).